Clifford Chance advises Keymed on out-licensing transaction with Timberlyne Therapeutics, Inc.
27 January 2025
- Yi Yang, Ryan Wong, Charmaine Lee, Matthew Warner, Daryl Fairbairn (He/Him), Vicki Ye, Renée Latour (She/Her), Holly Bauer (She/Her)
- Shanghai, Hong Kong, Beijing, New York, Shanghai, Washington D.C.
Clifford Chance advises Keymed on out-licensing transaction with Timberlyne Therapeutics, Inc.
Global law firm Clifford Chance has advised Keymed Biosciences (HKSe: 02162) on its out-licensing transaction with Timberlyne Therapeutics, Inc.
As part of the out-licensing transaction, Keymed has signed a licensing agreement granting Timberlyne the exclusive worldwide rights to develop, manufacture and commercialize CM313 (a potentially best-in-class humanized monoclonal antibody targeting CD38), excluding Greater China.
Timberlyne also closed its US$180 million Series A financing to advance the development of CM313. Investors Abingworth, Bain Capital Life Sciences, and Venrock Healthcare Capital Partners led the financing, with participation from Boyu Capital, Lilly Asia Ventures, Braidwell LP and 3H Health Investment. Upon closing of the Series A financing, Keymed holds 25.79% in Timberlyne, as its largest shareholder.
Lead partner Yang Yi said, "We are very honoured to have advised Keymed once again on this strategic overseas licensing transaction, which demonstrates our expertise in advising clients in the life science sector."
Yi was supported by a cross-border team of lawyers in Hong Kong, New York, and Washington D.C.:
- Beijing: Associate Xiaohan Sun
- Hong Kong: Counsel Ryan Wong, associate Charmaine Lee and trainee solicitor Luna Wang;
- New York: Partner Matthew Warner, counsel Daryl Fairbairn and associate Vicki Ye;
- Shanghai: Trainee solicitor Ashley Tan
- Washington D.C.: Partner Renee Latour and associate Holly Bauer.
Clifford Chance has an established track record of advising on major healthcare transactions in the Greater China region, including Sanofi's acquisition of exclusive Greater China rights to develop and commercialise Aficamten, Fosun Kairos' licensing agreement with Kite Pharma, and CBC Group and Mubadala's acquisition of UCB's mature business (neurology and allergy) in China.
高伟绅为康诺亚与Timberlyne的许可交易提供国际法律服务
国际领先律师事务所高伟绅近期就康诺亚生物医药科技有限公司(2162.HK)与Timberlyne Therapeutics, Inc.(以下简称Timberlyne)的许可交易提供国际法律服务。
康诺亚就潜在同类最优的靶向CD38人源化单克隆抗体CM313与Timberlyne订立独家授权许可协议,授予Timberlyne在全球(不包括中国内地、香港、澳门及台湾地区)开发、生产及商业化CM313的独家权利。
在订立授权许可协议的同时,Timberlyne还达成了1.8亿美金的A轮融资协议。本轮融资由贝恩资本生命科学(Bain Capital Life Sciences)、Venrock Healthcare Capital Partners和Abingworth三家知名基金领投,博裕资本、礼来亚洲基金(Lilly Asia Ventures)、Braidwell和三正健康投资(3H Health)等参与投资。A轮融资完成后,康诺亚将持有Timberlyne的25.79%股权,仍为其最大股东。
上海办公室合伙人杨毅表示:"我们非常荣幸能再次在这项战略性的出海交易中为康诺亚提供法律服务。这也展现了高伟绅团队在生命科学行业具备精深的专业能力。
本交易由杨毅和纽约办公室合伙人Matthew Warner共同领导。纽约办公室顾问律师Daryl Fairbairn和香港办公室顾问律师黄励行提供支持。其他团队成员还包括香港办公室李晓蓝和王思琪、上海办公室谈妍霏、北京办公室孙笑涵、纽约办公室Vicki Ye以及华盛顿特区办公室Renee Latour(合伙人)和Holly Bauer。
高伟绅在医疗保健和生命科学领域拥有突出业绩,近期经验包括:协助赛诺菲收购箕星药业在中国大陆及港澳台地区独家开发和商业化 Aficamten的权益,为康桥资本与穆巴达拉收购优时比在中国的成熟产品业务(神经系统和抗过敏产品)提供法律服务,以及就复星凯瑞与Kite Pharma的许可协议更新提供法律服务。